Moxibiot (Moxifloxacin)

Moxifloxacin, the active ingredient in Moxibiot, is a fluoroquinolone antibiotic presented as an intravenous injection for intravenous use. It is employed to treat serious bacterial infections such as community‑acquired pneumonia, acute bacterial sinusitis, skin and soft‑tissue infections, and complicated intra‑abdominal infections in adult patients. The drug works by inhibiting bacterial DNA replication, providing a broad spectrum of activity against Gram‑negative and Gram‑positive pathogens.

GNH USA supplies Moxibiot as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Moxifloxacin is a fluoroquinolone antibiotic that interferes with bacterial DNA synthesis, making it effective for a range of serious infections. - Community‑acquired pneumonia: achieves bacterial eradication and clinical cure in adult patients. - Acute bacterial sinusitis: reduces symptom duration and promotes rapid resolution of infection. - Skin and soft‑tissue infections: provides effective coverage against common Gram‑positive and Gram‑negative organisms. - Complicated intra‑abdominal infections: assists in controlling polymicrobial infections following surgical intervention.

Moxifloxacin may cause a range of adverse reactions, from mild to severe. Awareness of these effects helps clinicians monitor patients appropriately.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: often self‑limiting but may be watery. - Headache: transient and usually resolves without intervention. - Dizziness: occasional sensation of light‑headedness. - Rash: mild skin erythema or pruritus. - Photosensitivity: increased skin sensitivity to sunlight.

Serious or Rare Side Effects: - Tendon rupture: especially Achilles tendon, may occur without warning. - QT interval prolongation: can precipitate cardiac arrhythmias. - Severe allergic reactions: including anaphylaxis and Stevens‑Johnson syndrome. - Clostridioides difficile infection: may lead to severe colitis. - Hepatotoxicity: elevated liver enzymes or jaundice. - Peripheral neuropathy: rare sensory disturbances.

Moxifloxacin requires careful patient assessment and monitoring to minimize risks. - Assess renal function: adjust therapy in patients with impaired clearance. - Monitor for tendon pain: discontinue if signs of tendinopathy appear. - Check cardiac status: avoid in patients with known QT prolongation or arrhythmias. - Avoid use in patients with known hypersensitivity to fluoroquinolones. - Use with caution in pregnancy or breastfeeding: limited safety data available. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Moxifloxacin can interact with several drug classes, requiring vigilance.

Major Interactions (Avoid): - Concurrent QT‑prolonging agents: increased risk of torsades de pointes. - Antacids containing aluminum or magnesium: reduce moxifloxacin absorption. - Systemic corticosteroids: heightened risk of tendon rupture. - Warfarin: may potentiate anticoagulant effect and increase bleeding risk.

Moderate Interactions (Monitor Closely): - NSAIDs: may enhance central nervous system adverse effects. - Theophylline: possible increase in plasma theophylline concentrations. - Cyclosporine: may raise moxifloxacin levels, requiring dose adjustment.